

Global Human Growth Hormones Deficiency (GHD) Drugs Market Assessment: Current Market, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2023

- Global Human Growth Hormones (GH) Drugs Industry – Sizing, Growth and Forecast
- Global Human Growth Hormones Deficiency (GHD) Drugs Industry – Sizing, Growth and Forecast
- Global Human Growth Hormones Deficiency (GHD) Drugs Share By End User – Pediatric and Adult
- Global Human Growth Hormones Deficiency Pipeline Drugs Industry – Sizing, Growth and Forecast
- By Country – U.S, U.K, France, Spain, Germany and Japan
- Prominent Companies operating Global Human Growth Hormones Deficiency Pipeline Drugs



Human Growth Hormones Deficiency Drugs Market Assessment: Current Market, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2023


















<input type="checkbox"/> Scope of the Study	<input type="checkbox"/> Global Coverage	<input type="checkbox"/> Global hGH Market (2013-2023), By Value <input type="checkbox"/> Global hGHD Market (2013-2023), By Value		
Global Coverage	Regional Coverage	Country Coverage	Drug Coverage	Company Coverage
	<input type="checkbox"/> North America <input type="checkbox"/> Europe <input type="checkbox"/> ROW	<input type="checkbox"/> United States <input type="checkbox"/> United Kingdom <input type="checkbox"/> France <input type="checkbox"/> Spain <input type="checkbox"/> Germany <input type="checkbox"/> Japan	<input type="checkbox"/> Drug X1 <input type="checkbox"/> Drug X2 <input type="checkbox"/> Drug X3 <input type="checkbox"/> Drug X4	<input type="checkbox"/> Ascendis Pharma A/S <input type="checkbox"/> Novo Nordisk A/S <input type="checkbox"/> Versartis Inc. <input type="checkbox"/> Opko Health Inc. <input type="checkbox"/> Pfizer Inc.
<input type="checkbox"/> Global hGH Market (2013-2023), By Value				
<input type="checkbox"/> Global hGHD Market (2013-2023), By Value				
<input type="checkbox"/> Regional hGHD Market (2013-2023), By value				
<input type="checkbox"/> Country hGHD Market (2013-2023), By value	<input type="checkbox"/> hGHD Drugs Market, By Value (2013-2023)	<input type="checkbox"/> hGHD Drugs Market, By Value (2013-2023)	<input type="checkbox"/> Global hGHD Pipeline Drugs Market, By Value (2020-2023)	<input type="checkbox"/> Product Benchmarking <input type="checkbox"/> Policy and Regulatory Landscape <input type="checkbox"/> Financial Analysis <ul style="list-style-type: none"> <input type="checkbox"/> Sales <input type="checkbox"/> EBITDA <input type="checkbox"/> Business Strategy
<input type="checkbox"/> Global hGH Pipeline Drugs Market (2020-2023), By Value				

Table of Content

S.No	Particulars	Page No.
1.	Research Methodology	14
2.	Executive Summary	15
3.	Growth Hormone Deficiency Drugs Product - An Overview	16
3.1	Growth Hormone (GH) and its Function	16
3.2	Growth Hormone Deficiency (GHD) and its Symptoms	17
3.3	Causes of Growth Hormone Deficiency (GHD)	18
4.	Diagnosis of Growth Hormone Deficiency (GHD)	20
5.	Treatment of Growth Hormone Deficiency (GHD)	23
6.	Global Growth Hormone Drugs Market	25
6.1	Global Growth Hormone Drugs Market Size, By value, 2013-2017	26
6.2	Global Growth Hormone Drugs Market Size, By value, 2018-2023	27

Table of Content

S.No	Particulars	Page No.
7.	Global Growth Hormone Deficiency Drugs Market	31
7.1	Global Growth Hormone Deficiency Drugs Market Size, By value, 2013-2017	32
7.2	Global Growth Hormone Deficiency Drugs Market Size, By value, 2018-2023	33
8.	Global Growth Hormone Deficiency Drugs Market, By End User	35
8.1	Global Growth Hormone Deficiency Drugs Market, By End User : Break down (%)	35
8.1.1	Global Growth Hormone Deficiency Drugs Market, By End User : 2017%	36
8.1.2	Global Growth Hormone Deficiency Drugs Market, By End User : 2023%	36
8.2	Global Growth Hormone Deficiency Drugs Market, By End User – By Pediatrics	37
8.2.1	By Value (2013 – 2017)	38
8.2.2	By Value (2018 – 2023)	38
8.3	Global Growth Hormone Deficiency Drugs Market, By End User – By Adult	39
8.2.1	By Value (2013 – 2017)	39
8.2.2	By Value (2018 – 2023)	39

Table of Content

S.No	Particulars	Page No.
9.	Global Growth Hormone Deficiency Drugs Market : Regional Analysis	40
9.1	North America Growth Hormone Deficiency Drugs Market	40
9.1.1	By Value (2013 – 2017)	41
9.1.2	By Value (2018 – 2023)	41
9.2	Europe Growth Hormone Deficiency Drugs Market	42
9.2.1	By Value (2013 – 2017)	42
9.2.2	By Value (2018 – 2023)	42
9.3	ROW Growth Hormone Deficiency Drugs Market	43
9.3.1	By Value (2013 – 2017)	43
9.3.2	By Value (2018 – 2023)	43
10.	Global Growth Hormone Deficiency Drugs Market : Country Analysis	44
10.1	U.S. Growth Hormone Deficiency Drugs Market	44
10.1.1	By Value (2013 – 2017)	45
10.1.2	By Value (2018 – 2023)	45

Table of Content

S.No	Particulars	Page No.
10.2	U.K. Growth Hormone Deficiency Drugs Market	47
10.2.1	By Value (2013 – 2017)	47
10.2.2	By Value (2018 – 2023)	47
10.3	France Growth Hormone Deficiency Drugs Market	48
10.3.1	By Value (2013 – 2017)	48
10.3.2	By Value (2018 – 2023)	48
10.4	Germany Growth Hormone Deficiency Drugs Market	50
10.4.1	By Value (2013 – 2017)	50
10.4.2	By Value (2018 – 2023)	50
10.5	Spain Growth Hormone Deficiency Drugs Market	52
10.5.1	By Value (2013 – 2017)	52
10.5.2	By Value (2018 – 2023)	52

Table of Content

S.No	Particulars	Page No.
10.6	Japan Growth Hormone Deficiency Drugs Market	53
10.6.1	By Value (2013 – 2017)	53
10.6.2	By Value (2018 – 2023)	53
11.	human Growth Hormone Deficiency (hGHD) Pipeline Drugs Coverage	54
11.1	hGHD Pipeline Drugs – TransCon-hGH	55
11.1.1	Description	56
11.1.2	Regulatory Milestones	58
11.1.3	Advantages & Disadvantages	59
11.1.4	Product Profile & Launch Date	60
11.1.5	Clinical Trials and Status	63
11.1.6	Pivotal Clinical Trials and Results	66
11.1.7	TransCon-hGH – Global Market Potential	72
11.1.8	TransCon-hGH – 7Ps Analysis	74

Table of Content

S.No	Particulars	Page No.
11.2	hGHD Pipeline Drugs – Somapacitan	75
11.2.1	Description	76
11.2.2	Regulatory Milestones	77
11.2.3	Advantages & Disadvantages	78
11.2.4	Product Profile & Launch Date	79
11.2.5	Clinical Trials and Status	80
11.2.6	Pivotal Clinical Trials and Results	84
11.2.7	Somapacitan – Global Market Potential	86
11.2.8	Somapacitan – 7Ps Analysis	88
11.3	hGHD Pipeline Drugs – Somavaratan	89
11.3.1	Description	90
11.3.2	Regulatory Milestones	91
11.3.3	Advantages & Disadvantages	92

Table of Content

S.No	Particulars	Page No.
11.3.4	Product Profile & Launch Date	93
11.3.5	Clinical Trials and Status	95
11.3.6	Pivotal Clinical Trials and Results	100
11.3.7	Somavaratan – Global Market Potential	101
11.3.8	Somavaratan – 7Ps Analysis	103
11.4	hGHD Pipeline Drugs – Somatrogon/ Lagova	104
11.4.1	Description	105
11.4.2	Regulatory Milestones	106
11.4.3	Advantages & Disadvantages	107
11.4.4	Product Profile & Launch Date	108
11.4.5	Clinical Trials and Status	109
11.4.6	Pivotal Clinical Trials and Results	112

Table of Content

S.No	Particulars	Page No.
	11.4.7 Somatrogon/ Lagova – Global Market Potential	117
	11.4.8 Somatrogon/ Lagova – 7Ps Analysis	119
	11.5 Competitive Landscape	120
12.	Company Profile	121
	12.1 Ascendis Pharma A/S	122
	12.2 Novo Nordisk A/S	124
	12.3 Versartis Inc.	126
	12.4 Opko Health, Inc.	127
	12.5 Pfizer Inc.	128
13.	About Us	130

List of Figures

Figure No.	Figure Title	Page No.
Figure 1:	Global Growth Hormones Drugs Market Size, By value, 2013-2017 (USD Billion)	26
Figure 2:	Global Growth Hormones Drugs Market Size, By value, 2018-2023 (USD Billion)	27
Figure 3:	Global Growth Hormones Market Share 2017	28
Figure 4:	Sales of Growth Hormones, By Value, 2014-2017	28
Figure 5:	Global Growth Hormone Market Share, 2017 (%)	30
Figure 6:	Global Growth Hormones Deficiency Drugs Market Size, By value, 2013-2017 (USD Billion)	32
Figure 7:	Global Growth Hormones Deficiency Drugs Market Size, By value, 2018-2023 (USD Billion)	33
Figure 8:	Global Growth Hormone Market 2017	34
Figure 9:	Global Growth Hormone Market 2028	34
Figure 10:	Global Growth Hormone Deficiency Drugs Market Share, By End User, 2017 (%)	36
Figure 11:	Global Growth Hormone Deficiency Drugs Market Share, By End User, 2023 (%)	36
Figure 12:	Global Growth Hormone Deficiency Drugs Market, By Pediatrics, By Value, 2013-2017 (USD Billion)	38
Figure 13:	Global Growth Hormone Deficiency Drugs Market, By Pediatrics, By Value, 2018-2023 (USD Billion)	38
Figure 14:	Global Growth Hormone Deficiency Drugs Market, By Adults, By Value, 2013-2017 (USD Billion)	39
Figure 15:	Global Growth Hormone Deficiency Drugs Market, By Adults, By Value, 2018-2023 (USD Billion)	39
Figure 16:	North America Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)	41
Figure 17:	Europe Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)	42
Figure 18:	ROW Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)	43
Figure 19:	US Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)	45


List of Figures

Figure No.	Figure Title	Page No.
Figure 20:	U.S. Per Capita Health Expenditure, 2012-2016 (USD)	46
Figure 21:	U.S Prevalence of Cancer, in cases per 100,000 (2014-2016)	46
Figure 22:	UK Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)	47
Figure 23:	France Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)	48
Figure 24:	France Per Capita Healthcare Expenditure (USD)	49
Figure 25:	France Prevalence of Cancer, in cases per 100,000 (2014-2016)	49
Figure 26:	Germany Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)	50
Figure 27:	Germany Healthcare Expenditure (USD Billion, 2014-2017)	51
Figure 28:	Germany Prevalence of Cancer, in cases per 100,000 (2014-2016)	51
Figure 29:	Spain Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)	52
Figure 30:	Japan Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)	53
Figure 31:	Annualized Height Velocity (Mean + SD) of full dataset of 53 patients after 6 months of treatment	67
Figure 32:	Change in HT SDS (Mean + SD) of full dataset of 53 patients after 6 months of treatment	68
Figure 33:	Dose Proportional IGF-1 Elevation Observed Into the Normal Range	69
Figure 34:	Comparable hGH levels for TransCon Growth Hormone and Daily hGH	70
Figure 35:	Global TransCon hGH Market Size, By Value, Forecast, 2020-2023 (USD million)	72
Figure 36:	Annualized Height Velocity (Mean + SD) of full dataset of 53 patients after 6 months of treatment	85
Figure 37:	Global Somapacitan (NN8640) Market Size, By Value, Forecast, 2020-2023 (USD million)	86
Figure 38:	Height Velocity at 12 months in ITT and PP groups	100
Figure 39:	Global Somavaratan (VRS-317) Market Size, By Value, Forecast, 2020-2023 (USD million)	101

List of Figures

Figure No.	Figure Title	Page No.
Figure 40:	Mean annualized HV for subjects completed 24 month of once weekly Somatrogon treatment	114
Figure 41:	Mean annualized HV for subjects completed 24 month of once weekly Somatrogon treatment	114
Figure 42:	Global Somatrogon (Lagova) Market Size, By Value, Forecast, 2020-2023 (USD million)	117
Figure 43:	Ascendis Pharma Company Net Sales, By Value, in million €	123
Figure 44:	Novo Nordisk Company Net Sales, By Value, in million DKK	125
Figure 45:	Norditropin® net sales, by value, in million DKK	125
Figure 46:	Pfizer Company Revenue, By Value, in million USD	129
Figure 47:	Genotropin net sales, by value, in million USD	129
Table A:	Upcoming Drugs in the market of Growth Hormone Deficiency and their Clinical Status from 2016 - 2020	120

Research Methodology



For our study of human Growth Hormones Deficiency Pipeline Drugs Market, we have conducted comprehensive secondary research followed by an extensive primary research. In the process of secondary research, we have scrutinized industry documents, FDA approvals, company annual reports, clinical trial reports accessed from open sources, premium paid databases (Bloomberg, Thomson Reuters, Factiva) and our internal knowledge base. In the process of primary research, we have interviewed various industry experts across the value chain of the human Growth Hormone Drug industry.

Market size of the forecasted period (2020-2023) has been evaluated on the basis of growth in the number patients and anticipated price of pipeline drugs or treatment, and confirming the findings through primary research. Further more, for evaluating the market size of pipeline drugs annual reports of the companies are scanned to validate the launch date, estimated price and growth in the number of patients through primary and secondary research.


Report Focus: Global human Growth Hormones Deficiency Pipeline Drugs Market

- Global Coverage
- Regional Coverage (North America, Europe and ROW)
- Country Coverage (U.S, U.K, France, Germany, Spain and Japan)
- Company Coverage (Ascendis Pharma A/S, Novo Nordisk A/S, Versartis Inc, Opko Health Inc. and Pfizer Inc.)

Global Growth Hormone Drugs Market

Introduction of new and improved drugs along with growing health care expenditure is expected to drive global hGH market

Figure : Global Growth Hormones Drugs Market Size, By value, 2018-2023 (USD Billion)




Source: Azoth Analytics Estimates

- A Xxxxx
- A Xxxxx
- A Xxxxx
- A Xxxxx
- A xxxxx


Global Growth Hormone Deficiency Drugs Market - By End User

Figure : Global Growth Hormone Deficiency Drugs Market Share, By End User, 2017 (%)



Source: Azoth Analytics Estimates

Figure : Global Growth Hormone Deficiency Drugs Market Share, By End User, 2023 (%)




Source: Azoth Analytics Estimates

TransCon hGH

Pivotal Clinical Trials and Results


Figure : Change in HT SDS (Mean + SD) of full dataset of 53 patients after 6 months of treatment



Source : Ascendis Pharma Poster

Somavaratan (VRS-317) – Global Market Potential

Figure : Global Somavaratan (VRS-317) Market Size, By Value, Forecast, 2020-2023 (USD million)



Source: Azoth Analytics Estimates

- A xxxxx
- A Xxxxx
- A Xxxxx
- A Xxxxx
- A Xxxxx
- A Xxxxx
- A xxxxx

Somatrogon (Lagova) – 7Ps Analysis

Patent

Phase

Pathway

Patient

Physician

Payer

Partner

About Azoth Analytics Pvt Ltd.

Azoth Analytics is a business research and analytics firm that creates in-depth research reports and provides customized research solutions and consultancy Application. Verticals in which Azoth Analytics specializes include healthcare and pharmaceutical, oil and gas, retail, chemicals, automotive, FMCG, food & beverages and technology. Azoth creates comprehensive and in-depth research reports by recording, interpreting and analyzing information. Strategic market sizing and data dredging techniques include secondary research, and primary research (interviews with management personnel and industry experts).

Disclaimer: Azoth Analytics report information is based mainly on interviews and therefore, is subject to fluctuation. Azoth Analytics therefore, takes no responsibility for any incorrect information supplied to us by industry experts, manufacturers or users. Azoth does not warranty the completeness of the information and data. Also, analysis provided in the report are meant for customers' internal use only and not for general publication or disclosure to third parties.